Impact of Rosuvastatin Treatment on HDL-Induced PKC-βII and eNOS Phosphorylation in Endothelial Cells and Its Relation to Flow-Mediated Dilatation in Patients with Chronic Heart Failure

Figure 1

(a) X-fold increase in eNOS phosphorylation at Ser¹¹⁷⁷ of human aortic endothelial cells stimulated with HDL from patients treated with rosuvastatin or placebo versus unstimulated cells. (b) X-fold increase in eNOS phosphorylation at Thr⁴⁹⁵ of human aortic endothelial cells stimulated with HDL from patients treated with rosuvastatin or placebo versus unstimulated cells. (c) X-fold increase in PKC-βII phosphorylation at Ser⁶⁶⁰ of human aortic endothelial cells stimulated with HDL from patients treated with rosuvastatin or placebo versus unstimulated cells.

(a)

(b)

(c)